PubRank

Maurizio Bendandi

Author PubWeight™ 23.19‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 2006 2.69
2 Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007 1.35
3 IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol 2008 1.22
4 Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem 2006 1.19
5 Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 2004 1.13
6 CD28 aptamers as powerful immune response modulators. Mol Ther Nucleic Acids 2013 0.98
7 Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol 2007 0.93
8 Splenic marginal zone lymphoma with Evans' syndrome, autoimmunity, and peripheral gamma/delta T cells. Ann Hematol 2008 0.90
9 The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 2007 0.87
10 Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. Clin Cancer Res 2003 0.86
11 Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-cell malignancies. Haematologica 2004 0.85
12 Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. J Clin Oncol 2002 0.85
13 Prolonged idiotypic vaccination against follicular lymphoma. Leuk Lymphoma 2009 0.83
14 Feasibility of idiotype vaccination in relapsed B-cell malignancies. Haematologica 2003 0.81
15 Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development. Crit Rev Oncol Hematol 2004 0.81
16 Dendritic cell vaccination in glioblastoma after fluorescence-guided resection. World J Clin Oncol 2012 0.80
17 Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer. Expert Opin Biol Ther 2007 0.80
18 Autoimmunity and lymphoma: is mantle cell lymphoma a mistake of the receptor editing mechanism? Leuk Res 2009 0.79
19 Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: clinical and genetic features of two cases. Cancer Genet Cytogenet 2003 0.78
20 Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena. Clin Cancer Res 2006 0.77
21 Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses. Leuk Lymphoma 2004 0.77
22 Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming. Exp Hematol 2002 0.76
23 Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses. World J Clin Oncol 2011 0.76
24 Idiotype vaccines for lymphoma therapy. Expert Rev Vaccines 2011 0.75
25 Stem cell transplant and idiotypic vaccination for B-cell malignancies. Curr Top Med Chem 2011 0.75
26 Successful idiotypic vaccination following stem cell allotransplant in lymphoma. Leuk Lymphoma 2012 0.75
27 Idiotype vaccine production using hybridoma technology. Methods Mol Biol 2014 0.75
28 Non-radiolabelled PCR consensus primers and automatic sequencing enable rapid identification of tumor-specific V(H) CDR3 in aggressive B-cell malignancies. Leuk Lymphoma 2003 0.75
29 BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma. Expert Rev Vaccines 2011 0.75